Using Wolbachia bacteria to help stop malaria
Exploring Wolbachia for malaria control
Researchers plan to use Wolbachia bacteria in malaria mosquitoes to lower how often people in affected areas get malaria.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Michigan State University NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project ID | NIH-11241092 on NIH RePORTER |
What this research studies
From a patient's perspective, scientists will create mosquito lines that carry different Wolbachia bacteria and test whether those bacteria make mosquitoes less able to carry the malaria parasite. They will compare strains for how well they block Plasmodium, whether they survive high temperatures, and whether carrying Wolbachia makes the mosquitoes weaker or stronger. The team will study how mosquito and parasite genetics and environmental factors change the blocking effect, using laboratory infection experiments and mosquito fitness tests. Results will guide whether Wolbachia-based mosquito replacement could be safe and effective in malaria-affected communities.
Who could benefit from this research
Good fit: People living in malaria-endemic regions who face ongoing exposure to infected mosquitoes would be the primary beneficiaries of this work.
Not a fit: People who live outside malaria regions or who are not exposed to local mosquito transmission are unlikely to see direct benefit from this research.
Why it matters
Potential benefit: If successful, this approach could lower malaria transmission by making local mosquitoes less able to spread the parasite, reducing infections in communities.
How similar studies have performed: Wolbachia has been successfully used to curb dengue by modifying Aedes mosquitoes, and a single Wolbachia-infected Anopheles line (wAlbB in An. stephensi) showed reduced Plasmodium infection, but broad malaria control with this method remains largely unproven.
Where this research is happening
East Lansing, United States
- Michigan State University — East Lansing, United States (Active)
Researchers
- Principal investigator: Xi, Zhiyong — Michigan State University
- Study coordinator: Xi, Zhiyong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.